Subscribe To
Helocyte announces $3.22 million grant from the national cancer institute for triplex phase 2 clinical trial program
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-spec...
June 15, 2023, 12:00 pm